Clinical Trial Update: Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab with maintenance olaparib or maintenance pemetrexed as first-line therapy in metastatic nonsquamous non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Nonsquamous Non-small-cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2025-02-06